Another IDO1 inhibitor, BMS-986205, in combination with ipilimumab showed modest clinical benefit with an ORR of 26%.701 Clinical trials of other two IDO1 inhibitors, indoximod and navoximod demonstrated tolerable safety and antitumor efficacy worthy of further evaluations in advanced melanoma.702,703. The gene discussed is IDO1; the disease is melanoma.